Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

Rodney P. Rocconi; Elizabeth A. Grosen; Sharad A. Ghamande; John K. Chan; Minal A. Barve; Jonathan Oh; Devansu Tewari; Peter C. Morris; Erin E. Stevens; Justin N. Bottsford-Miller; Min Tang; Phylicia Aaron; Laura Stanbery; Staci Horvath; Gladice Wallraven; Ernest Bognar; Luisa Manning; John Nemunaitis; David Shanahan; Brian M. Slomovitz; Thomas J. Herzog; Bradley J. Monk; Robert L. Coleman

doi:10.1097/01.ogx.0000738108.04639.6f

Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

Rodney P. Rocconi, Elizabeth A. Grosen, Sharad A. Ghamande, John K. Chan, Minal A. Barve, Jonathan Oh, Devansu Tewari, Peter C. Morris, Erin E. Stevens, Justin N. Bottsford-Miller, Min Tang, Phylicia Aaron, Laura Stanbery, Staci Horvath, Gladice Wallraven, Ernest Bognar, Luisa Manning, John Nemunaitis, David Shanahan, Brian M. SlomovitzThomas J. Herzog, Bradley J. Monk, Robert L. Coleman

Obstetrics and Gynecology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	151-152
Number of pages	2
Journal	Obstetrical and Gynecological Survey
Volume	76
Issue number	3
DOIs	https://doi.org/10.1097/01.ogx.0000738108.04639.6f
State	Published - Mar 1 2021

ASJC Scopus subject areas

Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/01.ogx.0000738108.04639.6f

Cite this

Rocconi, R. P., Grosen, E. A., Ghamande, S. A., Chan, J. K., Barve, M. A., Oh, J., Tewari, D., Morris, P. C., Stevens, E. E., Bottsford-Miller, J. N., Tang, M., Aaron, P., Stanbery, L., Horvath, S., Wallraven, G., Bognar, E., Manning, L., Nemunaitis, J., Shanahan, D., ... Coleman, R. L. (2021). Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. Obstetrical and Gynecological Survey, 76(3), 151-152. https://doi.org/10.1097/01.ogx.0000738108.04639.6f

Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. / Rocconi, Rodney P.; Grosen, Elizabeth A.; Ghamande, Sharad A. et al.
In: Obstetrical and Gynecological Survey, Vol. 76, No. 3, 01.03.2021, p. 151-152.

Research output: Contribution to journal › Comment/debate › peer-review

Rocconi, RP, Grosen, EA, Ghamande, SA, Chan, JK, Barve, MA, Oh, J, Tewari, D, Morris, PC, Stevens, EE, Bottsford-Miller, JN, Tang, M, Aaron, P, Stanbery, L, Horvath, S, Wallraven, G, Bognar, E, Manning, L, Nemunaitis, J, Shanahan, D, Slomovitz, BM, Herzog, TJ, Monk, BJ & Coleman, RL 2021, 'Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial', Obstetrical and Gynecological Survey, vol. 76, no. 3, pp. 151-152. https://doi.org/10.1097/01.ogx.0000738108.04639.6f

@article{3eeb89e8a83b40ddaf7106f1bbc0cd11,

title = "Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial",

author = "Rocconi, {Rodney P.} and Grosen, {Elizabeth A.} and Ghamande, {Sharad A.} and Chan, {John K.} and Barve, {Minal A.} and Jonathan Oh and Devansu Tewari and Morris, {Peter C.} and Stevens, {Erin E.} and Bottsford-Miller, {Justin N.} and Min Tang and Phylicia Aaron and Laura Stanbery and Staci Horvath and Gladice Wallraven and Ernest Bognar and Luisa Manning and John Nemunaitis and David Shanahan and Slomovitz, {Brian M.} and Herzog, {Thomas J.} and Monk, {Bradley J.} and Coleman, {Robert L.}",

year = "2021",

month = mar,

day = "1",

doi = "10.1097/01.ogx.0000738108.04639.6f",

language = "English (US)",

volume = "76",

pages = "151--152",

journal = "Obstetrical and Gynecological Survey",

issn = "0029-7828",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL)

T2 - A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

AU - Rocconi, Rodney P.

AU - Grosen, Elizabeth A.

AU - Ghamande, Sharad A.

AU - Chan, John K.

AU - Barve, Minal A.

AU - Oh, Jonathan

AU - Tewari, Devansu

AU - Morris, Peter C.

AU - Stevens, Erin E.

AU - Bottsford-Miller, Justin N.

AU - Tang, Min

AU - Aaron, Phylicia

AU - Stanbery, Laura

AU - Horvath, Staci

AU - Wallraven, Gladice

AU - Bognar, Ernest

AU - Manning, Luisa

AU - Nemunaitis, John

AU - Shanahan, David

AU - Slomovitz, Brian M.

AU - Herzog, Thomas J.

AU - Monk, Bradley J.

AU - Coleman, Robert L.

PY - 2021/3/1

Y1 - 2021/3/1

UR - http://www.scopus.com/inward/record.url?scp=85161260849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85161260849&partnerID=8YFLogxK

U2 - 10.1097/01.ogx.0000738108.04639.6f

DO - 10.1097/01.ogx.0000738108.04639.6f

M3 - Comment/debate

AN - SCOPUS:85161260849

SN - 0029-7828

VL - 76

SP - 151

EP - 152

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

IS - 3

ER -

Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this